Mitochondrial Transcription Termination Factor 3: A Promising Drug Target

Target Name: MTERF3

NCBI ID: G51001

MTERF3

Mitochondrial Transcription Termination Factor 3: A Promising Drug Target

Mitochondrial Transcription Termination Factor 3 (MTERF3) is a non-coding RNA molecule that plays a critical role in regulating the process of mitochondrial transcription, which is the process by which the cell produces its DNA. MTERF3 is a key regulator of this process and is essential for the normal functioning of the mitochondria.

MTERF3 is composed of 194 amino acid residues and has a molecular weight of 21 kDa. It is highly conserved, with only one known splice variant. MTERF3 is predominantly expressed in the heart, brain, and testes, and is also expressed in other tissues and organs, including muscle, liver, and kidney.

MTERF3 is involved in the regulation of mitochondrial gene expression by binding to specific DNA sequences and preventing the translation of RNA into the mitochondrial matrix. This is accomplished through a process called RNA-protein interaction, which involves the formation of a protein-RNA complex and the inhibition of the activity of RNA-protein interactions by MTERF3.

MTERF3 is also involved in the regulation of mitochondrial translation by binding to the 26S rRNA and preventing its association with the ribosome. This is accomplished through a process called interaction with the 26S rRNA, which involves the formation of a protein-RNA complex and the inhibition of the activity of RNA-protein interactions by MTERF3.

MTERF3 is a key regulator of the mitochondrial transcriptional regulatory network and is involved in the regulation of a wide range of gene expression, including cell growth, differentiation, and stress responses. It is also involved in the regulation of mitochondrial dynamics, including mitochondrial fission and fusion.

MTERF3 is a potential drug target and has been identified as a therapeutic potential target for a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and diseases associated with inflammation.

One of the reasons why MTERF3 is a promising drug target is its involvement in the regulation of mitochondrial function and its role in the development and progression of a variety of diseases. MTERF3 is also involved in the regulation of cellular processes that are critical for human health , such as cell growth, differentiation, and stress responses.

In addition, MTERF3 is a good candidate for a drug because it is highly conserved and has a low expression level. This makes it easier to develop a drug that targets MTERF3 and to ensure that the drug will have a long-term effect on the cell.

Another reason why MTERF3 is a promising drug target is its involvement in the regulation of mitochondrial dynamics, including mitochondrial fission and fusion. MTERF3 is known to play a key role in regulating the dynamics of mitochondria and is involved in the regulation of

Protein Name: Mitochondrial Transcription Termination Factor 3

Functions: Binds promoter DNA and regulates initiation of transcription (PubMed:17662942). Required for normal mitochondrial transcription and translation, and for normal assembly of mitochondrial respiratory complexes. Required for normal mitochondrial function (By similarity). Maintains 16S rRNA levels and functions in mitochondrial ribosome assembly by regulating the biogenesis of the 39S ribosomal subunit (By similarity)

The "MTERF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTERF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets